A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment

NCT01287117 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

319

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Idiopathic Urticaria

Interventions

DRUG: Omalizumab
DRUG: Placebo

Sponsor

Genentech, Inc.